Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease in Clinical Practice.

NCT03459521 is registered in ClinicalTrials.gov with Corporacion Parc Tauli as lead sponsor.

NCT NCT03459521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03459521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease in Clinical Practice.
Lead sponsor
Corporacion Parc Tauli
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2017
Completion date
August 1, 2021
Enrollment
125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b virus, liver disease chronic